AUG 17, 2026 · PHASE 3 TRIAL
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
ClinicalTrials.gov
This is a clinical trial registry record describing a planned Phase 3 study with no results yet reported; the protocol and design are established but outcome data are absent.
Reported
Planned enrollment410
Study duration38 weeks
Primary outcome measureTime from randomization to relapse at Week…